120 related articles for article (PubMed ID: 28623781)
21. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
22. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.
Himmel DM; Das K; Clark AD; Hughes SH; Benjahad A; Oumouch S; Guillemont J; Coupa S; Poncelet A; Csoka I; Meyer C; Andries K; Nguyen CH; Grierson DS; Arnold E
J Med Chem; 2005 Dec; 48(24):7582-91. PubMed ID: 16302798
[TBL] [Abstract][Full Text] [Related]
23. Structural optimization of N
Monforte AM; De Luca L; Buemi MR; Agharbaoui FE; Pannecouque C; Ferro S
Bioorg Med Chem; 2018 Feb; 26(3):661-674. PubMed ID: 29291935
[TBL] [Abstract][Full Text] [Related]
24. Binding energy analysis for wild-type and Y181C mutant HIV-1 RT/8-Cl TIBO complex structures: quantum chemical calculations based on the ONIOM method.
Saen-oon S; Kuno M; Hannongbua S
Proteins; 2005 Dec; 61(4):859-69. PubMed ID: 16245320
[TBL] [Abstract][Full Text] [Related]
25. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 1).
Di Santo R; Costi R; Artico M; Miele G; Lavecchia A; Novellino E; Bergamini A; Cancio R; Maga G
ChemMedChem; 2006 Dec; 1(12):1367-78. PubMed ID: 17089433
[TBL] [Abstract][Full Text] [Related]
26. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity.
Smith MB; Lamb ML; Tirado-Rives J; Jorgensen WL; Michejda CJ; Ruby SK; Smith RH
Protein Eng; 2000 Jun; 13(6):413-21. PubMed ID: 10877852
[TBL] [Abstract][Full Text] [Related]
27. Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance.
Geitmann M; Unge T; Danielson UH
J Med Chem; 2006 Apr; 49(8):2375-87. PubMed ID: 16610781
[TBL] [Abstract][Full Text] [Related]
28. Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.
Frey KM
Future Microbiol; 2015; 10(11):1767-72. PubMed ID: 26517310
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
[TBL] [Abstract][Full Text] [Related]
30. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
31. Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors.
Stanton RA; Nettles JH; Schinazi RF
J Mol Model; 2015 Nov; 21(11):282. PubMed ID: 26450349
[TBL] [Abstract][Full Text] [Related]
32. Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
Sasaki T; Gannam ZTK; Kudalkar SN; Frey KM; Lee WG; Spasov KA; Jorgensen WL; Anderson KS
Bioorg Med Chem Lett; 2019 Aug; 29(16):2182-2188. PubMed ID: 31281023
[TBL] [Abstract][Full Text] [Related]
33. Assessing molecular docking tools for relative biological activity prediction: a case study of triazole HIV-1 NNRTIs.
Frączek T; Siwek A; Paneth P
J Chem Inf Model; 2013 Dec; 53(12):3326-42. PubMed ID: 24266618
[TBL] [Abstract][Full Text] [Related]
34. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
Bollini M; Domaoal RA; Thakur VV; Gallardo-Macias R; Spasov KA; Anderson KS; Jorgensen WL
J Med Chem; 2011 Dec; 54(24):8582-91. PubMed ID: 22081993
[TBL] [Abstract][Full Text] [Related]
35. Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
Wang J; Kang X; Kuntz ID; Kollman PA
J Med Chem; 2005 Apr; 48(7):2432-44. PubMed ID: 15801834
[TBL] [Abstract][Full Text] [Related]
36. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.
García-Sosa AT; Sild S; Takkis K; Maran U
J Chem Inf Model; 2011 Oct; 51(10):2595-611. PubMed ID: 21875140
[TBL] [Abstract][Full Text] [Related]
37. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
[TBL] [Abstract][Full Text] [Related]
38. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
39. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method.
Smith MB; Ruby S; Horouzhenko S; Buckingham B; Richardson J; Puleri I; Potts E; Jorgensen WL; Arnold E; Zhang W; Hughes SH; Michejda CJ; Smith RH
Drug Des Discov; 2003; 18(4):151-63. PubMed ID: 15553926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
